Company profile: BioAtla
1.1 - Company Overview
Company description
- Provider of conditionally active biologics (CABs) for cancer-targeted therapeutics activated under specific physiological conditions; the CIAO! platform for antibody optimization; CAB-ADCs, CAB-CAR-T, and CAB-Bispecifics to improve safety and efficacy; and Mecbotamab Vedotin, a CAB-AXL-ADC for AXL-expressing tumors evaluated in sarcoma and NSCLC.
Products and services
- Conditionally Active Biologics (CABs): Proprietary platform engineering therapeutics that switch activity under defined physiological conditions, focusing on cancer cells while sparing normal tissues for safer, more effective treatment
- CAB-ADCs: Conditionally-activated antibody-drug conjugates that target cancer cells while sparing normal cells, improving therapeutic index by reducing toxicity and enabling safer antitumor activity
- Mecbotamab Vedotin: A CAB-AXL-ADC, AXL-targeted, that attacks AXL-expressing tumors while reducing toxicity in normal tissues, currently evaluated for sarcoma and non-small cell lung cancer (NSCLC)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BioAtla
Argent Biopharma
HQ: Australia
Website
- Description: Provider of novel biopharmaceutical medications, developing and marketing treatments that address unmet medical needs, with a focus on central nervous system (CNS) and immune-related illnesses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Argent Biopharma company profile →
EpiBiologics
HQ: United States
Website
- Description: Provider of antibody-based targeted therapies and platforms for tissue-specific degradation of disease-driving membrane and extracellular proteins, including the EpiTAC platform (bispecific antibody system), AbTACs, KineTACs, TrainTAC degrader, and the EpiAtlas platform with a library of over 270 degrader arms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EpiBiologics company profile →
Aclaris Therapeutics
HQ: United States
Website
- Description: Provider of dermatologic and immuno-inflammatory therapies R&D, using its KINect platform to discover small-molecule kinase inhibitors; conducts clinical trials; offers drug discovery and early development via Confluence Discovery Technologies; advancing ATI-1777 (topical JAK1/JAK3), ATI-2138 (oral ITK/JAK3), and Zunsemetinib/ATI-450 (oral MK2) for metastatic breast cancer and pancreatic ductal adenocarcinoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aclaris Therapeutics company profile →
Principia Biopharma
HQ: United States
Website
- Description: Provider of pre-clinical discovery and development of differentiated oral small-molecule therapies for inflammatory and autoimmune diseases and cancer, addressing significant unmet medical needs in immunology and oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Principia Biopharma company profile →
Endpoint Health
HQ: United States
Website
- Description: Provider of precision immunology solutions, including targeted therapeutics tailored to patient biology for immune-mediated diseases, companion diagnostics to personalize treatment, a precision immunology ecosystem with pharma, biotech, diagnostics providers and clinical data registries, and clinical collaborations with over 60 global health systems to develop precision therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endpoint Health company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BioAtla
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BioAtla
2.2 - Growth funds investing in similar companies to BioAtla
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BioAtla
4.2 - Public trading comparable groups for BioAtla
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →